Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Down 6.3% in August

Cue Biopharma, Inc. (NASDAQ:CUE) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 3,430,000 shares, a decline of 6.3% from the August 15th total of 3,660,000 shares. Based on an average daily volume of 446,900 shares, the days-to-cover ratio is presently 7.7 days.

Institutional Trading of Cue Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Cue Biopharma in the second quarter valued at $66,000. Wedmont Private Capital increased its holdings in Cue Biopharma by 100.0% in the 1st quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock worth $76,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Cue Biopharma by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after acquiring an additional 150,457 shares during the period. Institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on CUE. Piper Sandler lowered their target price on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Stifel Nicolaus reduced their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Finally, JMP Securities decreased their price target on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a research note on Friday, July 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cue Biopharma presently has a consensus rating of “Buy” and an average target price of $5.00.

Cue Biopharma Trading Down 2.9 %

NASDAQ CUE opened at $0.55 on Thursday. Cue Biopharma has a 12 month low of $0.54 and a 12 month high of $3.25. The company has a current ratio of 2.06, a quick ratio of 2.06 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $26.93 million, a P/E ratio of -0.52 and a beta of 1.96. The business has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $1.32.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.09. Cue Biopharma had a negative net margin of 566.02% and a negative return on equity of 142.93%. The business had revenue of $2.66 million for the quarter, compared to analysts’ expectations of $1.12 million. During the same period in the previous year, the company earned ($0.29) earnings per share. On average, analysts predict that Cue Biopharma will post -0.87 EPS for the current fiscal year.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.